Am Tech Initiates Coverage ON Schering-Plough (SGP) With A Buy
More News related to SGP
- FDA Says It Is Investigating Potential Link Between Vytorin and Risk of Cancer (MRK, SGP)
- Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
- Schering-Plough (SGP) Reports July Vytorin/Zetia Volume
- Gates' The Bill and Melinda Gates Foundation Shows New Positions in Crocs (CROX), Dick's (DKS) and Raised Stakes in McDonald's (MCD), FedEx (FDX) and AIG (AIG)
- Schering-Plough Expands Its Presence in China, Enters Next Stage of Development
More News related to Analyst Comments
- Merrill Lynch Downgrades Abercrombie & Fitch (ANF) to Underperform
- Deutsche Bank Lowers Rating On UST Inc (UST) From Buy To Hold
- Lazard Downgrades Navios Maritime (NM) to Hold
- B. Riley Downgrades Captaris (CAPA) to Neutral
- Lazard Downgrades Genco Shipping (GNK) to Hold
Today, American Technology Research initiates coverage on Schering-Plough (NYSE: SGP) with a Buy and a $26 price target, which is 36% upside from here.
Am Tech said Schering-Plough has been hit hard in the first half of this year with concerns regarding its Vytorin/Zetia franchise, but Am Tech believes that management now has a clear financial grip on the situation and has reacted fast (cut costs) to mitigate the impact. Based on Am Tech's conversations with physicians and thought leaders, it believes that the cholesterol prescriptions are nearing a bottom, and will likely stabilize in the coming weeks.
Also, Am Tech said Schering-Plough's key pipeline asset - suggamadex - an anesthesiology reversal-agent, is exciting, with most physicians referring to it as a game-changing product in anesthesiology. Am Tech expects suggamadex to gain FDA approval on its PDUFA date of August 2, 2008.
Am Tech believes investors should be buying SGP at current levels.
Schering-Plough Corporation is a global science-based healthcare company with prescription, consumer and animal health products.
Sign up at EasyStockAlerts.com To Be Alerted To Your Stock News Today!
Related Categories
Analyst CommentsInsiders' Blog
Stocks Mentioned
+0.10Related Entities
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
suggamadex
deborah on Aug 1, 2008 11:32 AMsuggamadex did not gain FDA approval